Dal Negro Roberto W, Paoletti Matteo, Pistolesi Massimo
National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology - CESFAR, Verona.
Department of Experimental and Clinical Medicine, University of Florence, Italy.
Multidiscip Respir Med. 2021 Dec 6;16(1):805. doi: 10.4081/mrm.2021.805. eCollection 2021 Jan 15.
Chronic obstructive pulmonary disease (COPD) is a generic term identifying a condition characterized by variable changes in peripheral airways and lung parenchyma. Standard spirometry cannot discriminate the relative role of conductive airways inflammatory changes from destructive parenchymal emphysema changes. The aim of this study was to quantify the emphysema component in COPD by a simple parameter (the Emphysema Severity Index - ESI), previously proved to reflect CT-assessed emphysema.
ESI was obtained by fitting the descending limb of MEFV curves by a fully automated procedure providing a 0 to 10 score of emphysema severity. ESI was computed in COPD patients enrolled in the CLIMA Study.
The vast majority of ESI values ranged from 0 to 4, compatible with no-to-mild/moderate emphysema component. A limited proportion of patients showed ESI values >4, compatible with severe-to-very severe emphysema. ESI values were greatly dispersed within each GOLD class indicating that GOLD classification cannot discriminate emphysema and conductive airways changes in patients with similar airflow limitation. ESI and diffusing capacity (DL) were significantly correlated (p<0.001). However, the great dispersion in their correlation suggests that ESI and DL reflect partially different anatomo-functional determinants in COPD.
Airflow limitation has heterogenous determinants in COPD. Inflammatory and destructive changes may combine in CT densitometric alterations that cannot be detected by standard spirometry. ESI computation from spirometric data helps to define the prevailing pathogenetic mechanism underlying the measured airflow limitation. ESI could be a reliable advancement to select large samples of patients in clinical or epidemiological trials, and to compare different pharmacological treatments.
慢性阻塞性肺疾病(COPD)是一个通用术语,用于描述以外周气道和肺实质发生可变变化为特征的病症。标准肺量计无法区分传导性气道炎症变化与实质性肺气肿破坏变化的相对作用。本研究的目的是通过一个简单参数(肺气肿严重程度指数 - ESI)对COPD中的肺气肿成分进行量化,该参数先前已被证明可反映CT评估的肺气肿情况。
通过全自动程序拟合MEFV曲线的下降支来获得ESI,该程序可提供0至10分的肺气肿严重程度评分。对纳入CLIMA研究的COPD患者计算ESI。
绝大多数ESI值范围为0至4,与无至轻度/中度肺气肿成分相符。有限比例的患者显示ESI值>4,与重度至极重度肺气肿相符。ESI值在每个GOLD分级内差异很大,表明GOLD分级无法区分气流受限程度相似的患者中的肺气肿和传导性气道变化。ESI与弥散能力(DL)显著相关(p<0.001)。然而,它们相关性的巨大差异表明,ESI和DL在COPD中反映了部分不同的解剖功能决定因素。
气流受限在COPD中有多种决定因素。炎症和破坏变化可能共同导致CT密度测定改变,而标准肺量计无法检测到这些改变。根据肺量计数据计算ESI有助于确定所测气流受限背后的主要发病机制。ESI可能是一项可靠的进展,可用于在临床或流行病学试验中选择大量患者样本,并比较不同的药物治疗。